(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 34.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Ocular Therapeutix's revenue in 2025 is $61,441,000.On average, 4 Wall Street analysts forecast OCUL's revenue for 2025 to be $11,021,256,068, with the lowest OCUL revenue forecast at $10,250,576,240, and the highest OCUL revenue forecast at $11,822,750,510. On average, 3 Wall Street analysts forecast OCUL's revenue for 2026 to be $14,191,388,266, with the lowest OCUL revenue forecast at $10,816,558,978, and the highest OCUL revenue forecast at $20,391,100,282.
In 2027, OCUL is forecast to generate $25,100,705,525 in revenue, with the lowest revenue forecast at $20,155,274,141 and the highest revenue forecast at $30,170,024,241.